Researchers showed that mucosally delivered L. lactis expressing Group A Streptococcus pili generates specific antibody responses in rabbits. Rabbit anti-pilus antibodies were shown to have both a neutralizing effect on bacterial adhesion, and immunized rabbit antiserum was able to facilitate immune-mediated killing of bacteria via opsonophagocytosis. [Sci Rep]
Full Article

HIV

Compared with β2-microglobulin and HLA-A11, the heterodimer of HLA-A11svE4 and HLA-A11 protected target cells from lysis by NK cells more effectively. HLA-AsvE4 expression was upregulated by HIV-1 in vivo and by HSV, CMV, and hepatitis B virus in vitro. [J Immunol]
Abstract | Full Article

Scientists present a complete picture of the Zika virus monoclonal antibodies and then focus on the neutralizing mechanisms and immune hot spot uncovered through structural studies, which provide insight for therapeutics and vaccine design. [J Virol]
Abstract | Full Article

Visit our
reviews
page to see a complete list of reviews in
the immunology of infectious disease research field.

The FDA approved Mavyret to treat adults with chronic hepatitis C virus genotypes 1-6 without cirrhosis or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. [FDA]
Press Release

The Centers for Disease Control and Prevention (CDC) has awarded more than $200 million through the Epidemiology and Laboratory Capacity for Infectious Diseases cooperative agreement to help states, cities, counties, and territories prevent, detect, respond to, and control the growing threats posed by emerging and re-emerging infectious diseases. [Centers for Disease Control and Prevention]
Press Release

Thousands of scientists, university students and science enthusiasts gathered in dozens of Indian cities to march in support of science — lamenting their country’s low levels of funding for research, and complaining about government promotion of ‘unscientific ideas’. [Nature News]
Editorial

The New York-based doctor who helped a couple have a child using DNA from three people has been told by the U.S. FDA that he can’t go ahead with clinical trials meant to test the technique. [MIT Technology Review]
Editorial

MilliporeSigma, a subsidiary of pharmaceutical giant Merck KGaA of Darmstadt, Germany, has become a new major player in the complicated European patent battles over CRISPR, the revolutionary genome-editing tool. [ScienceInsider]
Editorial